Belgium’s chemical and pharmaceutical sector faced another significant setback in 2025, with 1,590 jobs lost across the country, according to data released by industry federation Essenscia. The figures, published on Wednesday, April 22, 2026, show that 1,503 of these job losses occurred in Flanders, while the remainder affected other regions. The majority of the decline was concentrated in the chemical industry, highlighting ongoing structural challenges within the sector.
The latest data adds to a concerning trend, following 1,150 job losses recorded in 2024. Together, these figures indicate a sustained period of workforce reduction that has raised alarms among policymakers, labor unions and industry stakeholders. Beyond employment, the sector also experienced a notable downturn in investment, with research and development spending declining for the first time in a decade during 2025.
The chemical and pharmaceutical industries have long been pillars of Belgium’s economy, particularly in regions like Antwerp, where major industrial clusters have historically driven innovation and export growth. However, rising energy costs, global competition, and shifting production strategies have prompted several companies to scale back operations or relocate parts of their value chains abroad. These pressures have contributed to the erosion of domestic job bases despite the sector’s historical strength.
Essenscia, which represents companies across the chemical, plastics, and life sciences sectors, has been monitoring these trends closely. The federation’s reports serve as a key barometer for the health of one of Belgium’s most critical industrial ecosystems. While the data reflects real economic pressures, it also underscores the necessitate for coordinated policy responses aimed at preserving competitiveness, supporting innovation, and safeguarding skilled employment.
Industry analysts point to a combination of factors behind the downturn, including elevated electricity and gas prices compared to neighboring countries, increased regulatory complexity, and the relocation of certain manufacturing activities to regions with lower operational costs. At the same time, some firms continue to invest in high-value activities such as specialty chemicals and biopharmaceutical research, suggesting a potential shift in the sector’s composition rather than a uniform decline.
Looking ahead, stakeholders are calling for targeted interventions to address the root causes of deindustrialization risks. Proposals include reforming energy taxation, expanding support for green transition initiatives, and strengthening public-private partnerships in research and development. The Belgian government has previously engaged with European Commission-led efforts, such as the “Green Deal Industrial Plan,” to bolster resilience in energy-intensive industries.
As of now, no official timeline has been released for the next comprehensive update on employment or investment trends in the chemical and pharmaceutical sectors. Stakeholders await the next scheduled reporting cycle from Essenscia, which typically provides semi-annual assessments of industry performance.
For ongoing coverage of industrial trends, economic policy, and sector-specific developments in Belgium and beyond, readers are encouraged to follow updates from verified economic institutions and reputable financial news outlets.
Share your thoughts on the future of Belgium’s industrial base in the comments below, and help spread awareness by sharing this article with your network.